Table 4. . Baseline quality of life scores.
| Study | Treatment | Scale | Baseline global QoL | Fatigue | Pain | Cough | Dyspnea | Ref. |
|---|---|---|---|---|---|---|---|---|
| LUME-Lung 1 | Docetaxel + placebo Docetaxel + nintedanib |
EORTC QLQ-LC13 and EORTC QLQ-C30 |
62.3 61.2 |
– | 27.6 27.0 |
35.9 39.6 |
28.3 29.8 |
[4,17] |
| CheckMate 017 | Nivolumab Docetaxel |
LCSS ASBI |
29.6 29.6 |
– | – | – | – | [13,16] |
| BR.21 | Erlotinib Placebo |
EORTC QLQ-LC13 and EORTC QLQ-C30 |
55.3 53.5 |
42.5 45.4 |
34.2 38.3 |
43.4 39.0 |
31.9 33.5 |
[18,19] |
| TAX-317 | Docetaxel Best supportive care |
LCSS | 64.6 66.8 |
63.5 62.8 |
74.7 76.1 |
70.3 66.2 |
63.7 70.4 |
[23] |
ASBI: Average Symptom Burden Index; EORTC: European Organization for Research and Treatment of Cancer; EORTC QLQ-C30: EORTC multidimensional core questionnaire; EORTC QLQ-LC13: EORTC lung cancer questionnaire; LCSS: Lung Cancer Symptom Scale; QoL: Quality of life.